Detalhe da pesquisa
1.
Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium.
Am Heart J
; 187: 156-169, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28454799
2.
Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators.
Am Heart J
; 169(3): 305-14, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25728719
3.
Site selection for heart failure clinical trials in the USA.
Heart Fail Rev
; 20(4): 375-83, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25649127
4.
Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries.
Am Heart J
; 168(2): 142-9, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25066552
5.
High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis.
J Pediatr Gastroenterol Nutr
; 59(6): 767-72, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25419597
6.
Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis.
Ther Innov Regul Sci
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38632158
7.
Statistical power considerations in the use of win ratio in cardiovascular outcome trials.
Contemp Clin Trials
; 124: 107040, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36470557
8.
Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group.
Circ Heart Fail
; 15(6): e009038, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35331001
9.
Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
Gastroenterology
; 138(4): 1286-96, 1296.e1-3, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20064514
10.
Developing New Treatments for Heart Failure: Focus on the Heart.
Circ Heart Fail
; 9(5)2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27166246
11.
Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction.
Circ Heart Fail
; 9(11)2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27756791
12.
The effect of isoproterenol on the class III effect of azimilide in humans.
J Cardiovasc Pharmacol Ther
; 7(4): 211-7, 2002 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-12490966
13.
Developing therapies for heart failure with preserved ejection fraction: current state and future directions.
JACC Heart Fail
; 2(2): 97-112, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24720916
14.
Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial.
J Am Coll Cardiol
; 52(13): 1076-83, 2008 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-18848141